Upadacitinib Maintenance Triples Clinical Remissions in Crohn's Disease

(MedPage Today) -- Depending on the dose, maintenance upadacitinib (Rinvoq) either doubled or tripled clinical remissions at 1 year in patients with moderately to severely active Crohn's disease, the phase III U-ENDURE trial showed. In an intention...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news